Welcome to our dedicated page for Owlet news (Ticker: OWLT), a resource for investors and traders seeking the latest updates and insights on Owlet stock.
Owlet, Inc. (NYSE: OWLT) is a pediatric health platform known for smart infant monitoring devices, pediatric wearables, and connected nursery technology. The OWLT news feed on Stock Titan aggregates company announcements, press releases, and market updates so readers can follow how Owlet’s products, partnerships, and financial performance evolve over time.
News about Owlet often covers product launches and regulatory milestones, such as the TGA‑approved rollout of Dream Sock in Australia and New Zealand, the introduction of the Owlet360 subscription service in markets like the UK and Ireland, and cybersecurity certifications for the Dream Sight camera. Articles also highlight collaborations that connect BabySat infant pulse oximeter data into remote patient monitoring platforms and electronic health record workflows through partners including Locus Health and Rhapsody.
Investors and parents can use this page to review updates on Owlet’s DME and insurance‑supported distribution channels, including its partnership with 1 Natural Way, as well as recognition such as inclusion on Fast Company’s Brands That Matter list. The feed also captures earnings releases, guidance updates, and SEC‑related communications that reflect Owlet’s positioning as a small‑cap healthcare growth equity company in the digital health and medical device space.
By checking this OWLT news page regularly, readers can track developments in Owlet’s pediatric wearables, subscription services like Owlet360, international expansion, clinical integrations, and corporate actions that may influence the outlook for Owlet stock and its role in connected infant care.
Owlet (NYSE: OWLT) reported Q1 2026 revenue of $22.5M (up 6.4% YoY) and record subscription revenue of $2.7M. Q1 gross margin was 54.5%; net loss was $3.3M. Subscriptions reached over 115,000 paying users. 2026 guidance updated to $118–122M revenue and adjusted EBITDA of $7–9M.
Owlet (NYSE: OWLT) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a conference call the same day at 4:30 p.m. ET featuring CEO Kurt Workman and CFO Amanda Twede Crawford.
Dial-in numbers, Meeting ID 479023892, and a simultaneous webcast at the company's Investor Relations site will be available; a replay will follow.
Owlet (NYSE: OWLT) launched Owlet for Orgs, an employer benefit program giving companies access to FDA-cleared infant monitoring products for new and expecting parents. The program offers the Dream Sock pulse-oximeter and the Dream Duo 3 bundle with Dream Sight video, and names VGM Group as inaugural partner.
The service integrates with HR and benefits teams to customize rollouts, aims to improve employee peace of mind and retention, and complements Owlet’s existing product ecosystem including BabySat and Owlet Cares partnerships.
Owlet (NYSE: OWLT) announced that Dream Duo 3 was named “Best for Monitoring Baby's Health” in the PARENTS 2026 Best for Baby Awards. Dream Duo 3 pairs the FDA-cleared Dream Sock with the SGS-certified Dream Sight video monitor, delivering clinical vitals and 2K HD video.
The platform is used by more than 2.5 million families and is sold direct and through major retailers globally.
Owlet (NYSE: OWLT) announced an immediate CEO transition: Jonathan Harris resigned and co-founder Kurt Workman returns as President and CEO, remaining a director. The Board reaffirmed Q1 2026 revenue guidance with results expected at the high end of the guidance range.
The company will report Q1 2026 results in early May 2026, emphasizes a commitment to profitability, and noted its Q1 estimates are preliminary and unaudited. CFO Amanda Twede Crawford elected to receive 100% of her 2025 bonus in Owlet common stock.
Owlet (NYSE: OWLT) donated $39,000 in medical‑grade monitoring products to Children's Hospital Los Angeles' Newborn Intensive Critical Care Unit as part of CHLA's 11th annual Make March Matter campaign.
The contribution includes Dream Sock monitors, Dream Duo 3 bundles, and swaddles, and complements Owlet Cares' broader giving and FDA‑cleared product availability efforts.
Owlet (NYSE: OWLT) reported record FY2025 revenue of $105.7M (up 35.4% YoY) and record gross profit of $53.5M with a 50.6% gross margin. Q4 revenue was $26.6M (+29.6% YoY). FY2025 net loss was $39.7M including a $26.6M non-cash warrant mark-to-market adjustment. The company closed 2025 with adjusted EBITDA of $2.0M and initiated 2026 guidance: revenue $126–$130M, gross margin 49%–52%, and adjusted EBITDA $3–$5M.
Owlet (NYSE: OWLT) named Hannah Cranston Media as its public relations agency of record on February 24, 2026. Owlet highlighted its scale—having monitored more than 2.5 million babies across 30+ countries—recent regulatory clearance in India and product lineup including Dream Sock, Dream Sight, Dream Duo Gen 3, BabySat, and Owlet360 with >110k subscribers.
The agreement covers global earned media, PR strategy, AI search optimization, and support for international expansion, DME partnerships, and investor outreach as Owlet broadens its pediatric wellness footprint.
Owlet (NYSE: OWLT) will release fourth quarter and full year 2025 results after market close on March 5, 2026. A conference call with CEO Jonathan Harris and CFO Amanda Twede Crawford is set for 4:30 p.m. ET the same day, with webcast access and a replay on the investor site.
Dial-in numbers and an access code are provided for live participation; the webcast will be available in the Events section of the company investor relations website.
Owlet (NYSE: OWLT) announced a strategic partnership with PromptCare to expand DME distribution of its pediatric, FDA-cleared pulse oximeter BabySat.
The collaboration leverages PromptCare’s >40 years in respiratory care and 25+ U.S. locations to access pediatric hospital-to-home pathways, pilot deployments, and expected incremental unit shipments as pilots scale.